TransCode says preclinical study shows survival benefit for TTX-MC138 in breast cancer bone metastasis model
RNAZ•Preclinical study shows survival benefit in mouse model
TransCode Therapeutics disclosed peer-reviewed preclinical data showing its lead candidate TTX-MC138 extended survival in a breast cancer bone-metastasis mouse model.
- The study reported drug accumulation in bone lesions following systemic dosing, with reduced miR-10b expression and increased HOXD10 tumor-suppressor expression.
- Repeated dosing was well tolerated, with no systemic toxicity observed during the study.
- Results were published online Aug. 23, 2026 in Cancers, supporting potential expansion of miR-10b inhibition into additional metastatic settings.
